Document Type
Journal Article
Publication Date
1-1-2014
Journal
Orphanet Journal of Rare Diseases
Volume
9
DOI
10.1186/s13023-014-0130-8
Abstract
Methylmalonic and propionic acidemia (MMA/PA) are inborn errors of metabolism characterized by accumulation of propionic acid and/or methylmalonic acid due to deficiency of methylmalonyl-CoA mutase (MUT) or propionyl-CoA carboxylase (PCC). MMA has an estimated incidence of ~ 1: 50,000 and PA of ~ 1:100'000 -150,000. Patients present either shortly after birth with acute deterioration, metabolic acidosis and hyperammonemia or later at any age with a more heterogeneous clinical picture, leading to early death or to severe neurological handicap in many survivors. Mental outcome tends to be worse in PA and late complications include chronic kidney disease almost exclusively in MMA and cardiomyopathy mainly in PA. Except for vitamin B12 responsive forms of MMA the outcome remains poor despite the existence of apparently effective therapy with a low protein diet and carnitine. This may be related to under recognition and delayed diagnosis due to nonspecific clinical presentation and insufficient awareness of health care professionals because of disease rarity.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
APA Citation
Baumgartner, M., Hörster, F., Dionisi-Vici, C., Haliloglu, G., Karall, D., Chapman, K. A., & +19 additional authors (2014). Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia.. Orphanet Journal of Rare Diseases, 9 (). http://dx.doi.org/10.1186/s13023-014-0130-8
Peer Reviewed
1
Open Access
1
Comments
Reproduced with permission of BioMed Central Ltd. Orphanet Journal of Rare Diseases.